Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by LUHUA WANG and LIANG ZHANG.
LUHUA WANG
Connection Strength
3.329
LIANG ZHANG
  1. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504.
    View in: PubMed
    Score: 0.456
  2. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol. 2013 Jun; 9(6):495-7.
    View in: PubMed
    Score: 0.449
  3. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep; 84(9):553-9.
    View in: PubMed
    Score: 0.346
  4. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
    View in: PubMed
    Score: 0.157
  5. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45.
    View in: PubMed
    Score: 0.129
  6. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41.
    View in: PubMed
    Score: 0.120
  7. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56.
    View in: PubMed
    Score: 0.117
  8. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014 Feb; 28(2):407-10.
    View in: PubMed
    Score: 0.114
  9. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013 Aug 02; 6:55.
    View in: PubMed
    Score: 0.113
  10. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16.
    View in: PubMed
    Score: 0.113
  11. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.
    View in: PubMed
    Score: 0.111
  12. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92.
    View in: PubMed
    Score: 0.107
  13. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.
    View in: PubMed
    Score: 0.105
  14. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8.
    View in: PubMed
    Score: 0.100
  15. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011 Mar 26; 71(5):625-49.
    View in: PubMed
    Score: 0.096
  16. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6.
    View in: PubMed
    Score: 0.094
  17. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009 Jul; 23(7):1320-8.
    View in: PubMed
    Score: 0.083
  18. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60.
    View in: PubMed
    Score: 0.078
  19. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008 Feb; 83(2):144-9.
    View in: PubMed
    Score: 0.078
  20. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85.
    View in: PubMed
    Score: 0.076
  21. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62.
    View in: PubMed
    Score: 0.073
  22. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jul; 6(7):983-91.
    View in: PubMed
    Score: 0.069
  23. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
    View in: PubMed
    Score: 0.031
  24. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93.
    View in: PubMed
    Score: 0.030
  25. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4.
    View in: PubMed
    Score: 0.027
  26. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9.
    View in: PubMed
    Score: 0.022
  27. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Oct 15; 110(8):3028-35.
    View in: PubMed
    Score: 0.019
  28. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.